Welcome to our dedicated page for Aehr Test Sys SEC filings (Ticker: AEHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aehr Test Systems filings document material events, operating results, capital actions and governance matters for a semiconductor test and burn-in equipment company. Recent Form 8-K disclosures include quarterly financial-result releases covering revenue, bookings, backlog, cash position and GAAP and non-GAAP earnings measures.
The filing record also includes capital-structure disclosures tied to an at-the-market common stock offering under a Form S-3 registration statement, along with proxy and annual meeting materials. Those governance filings address director elections, shareholder voting results, amendments to the company’s equity incentive and employee stock purchase plans, auditor ratification and executive-compensation matters.
AEHR TEST SYSTEMS Chief Operating Officer Adil Engineer reported routine equity compensation transactions. On April 1, 2026, he acquired 2,454 shares of common stock at $6.6725 per share through the company’s Amended and Restated 2006 Employee Stock Purchase Plan, described as a tax-conditioned plan under Internal Revenue Code Section 423.
On April 2, 2026, 458 shares of common stock valued at $44.32 per share were withheld to satisfy tax obligations upon vesting of restricted stock units, which the disclosure states does not represent a sale by the reporting person. After these transactions, Engineer directly owned 47,672 shares of common stock, and this amount includes shares subject to unvested restricted stock units.
The Vanguard GroupSchedule 13G reporting zero shares beneficially owned of Aehr Test Systems Common Stock as of 03/13/2026. The amendment explains an internal realignment effective 01/12/2026 that disaggregated certain subsidiaries and business divisions for reporting under SEC Release No. 34-39538.
The filing states Vanguard’s subsidiaries now report separately and that Vanguard no longer is deemed to have beneficial ownership of securities held by those entities.
Aehr Test Systems director Geoffrey Scott reported a charitable stock transfer. On a Form 4, he disclosed a bona fide gift of 5,104 shares of common stock to the Scott Family Fund. After the donation, he directly owns 52,864 shares and indirectly holds 60,686 shares through a trust and 140,000 shares through his spouse, with some amounts including unvested restricted stock units.
AEHR Test Systems Executive VP of R&D Didier Wimmers reported a tax-related share withholding tied to restricted stock units. On March 3, 2026, 364 shares of common stock were withheld at $41.64 per share to cover tax obligations, not as an open-market sale. Following this, he held 14,186 shares, which the disclosure notes includes unvested restricted stock units.
AEHR TEST SYSTEMS CFO Chris Siu reported a tax-related share withholding transaction. On March 1, 2026, 368 shares of common stock were withheld at $37.43 per share to satisfy tax obligations upon vesting of restricted stock units, which the footnotes clarify does not represent a sale by the reporting person.
Following this transaction, Siu directly owned 72,258 shares of common stock, and an additional 5,211 shares were held indirectly by a trust. The indirect position is reported as a holding entry, without a specified buy or sell action.
AEHR filed a notice under Rule 144 for a planned sale of 13,998 shares of its common stock. The shares are expected to be sold through Oppenheimer & Co. on the NASDAQ around 02/13/2026, with an aggregate market value listed as 390404.22.
The securities were originally acquired from the issuer on 10/18/2023 as compensation, in a single transaction for 13,998 shares. The filing notes that 30,627,342 shares of this class were outstanding, providing context for the size of the planned sale.
Aehr Test Systems director Rhea J. Posedel reported an insider sale of common stock through a trust associated with her. On February 13, 2026, the trust sold 13,998 shares of Aehr Test Systems common stock in an open-market transaction at $30.0151 per share.
After this transaction, the trust continued to hold 456,979 shares indirectly. Posedel also directly held 71,163 shares, and this direct amount includes shares subject to unvested restricted stock units.
Aehr Test Systems officer Alistair N. Sporck reported selling company stock. On 02/09/2026, Sporck, VP Contactor Business Unit, sold 2,700 shares of common stock at $27.57 per share and 300 shares at $27.59 per share, leaving 25,153 shares held directly and 5,214 shares held indirectly by a trust, which include shares subject to unvested restricted stock units.
A shareholder of AEHR has filed a Rule 144 notice to sell 3,000 shares of common stock, with an aggregate market value of $82,715.25. The planned sale is through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/09/2026.
The filing notes that 30,627,342 shares of common stock were outstanding. The 3,000 shares to be sold were acquired through multiple restricted stock vesting compensation events between 10/02/2025 and 01/27/2026, with each vesting treated as compensation from the issuer.
Baillie Gifford & Co has reported a passive stake in AEHR Test Systems’ common stock below the 5% threshold. The firm beneficially owns 1,290,734 shares, representing 4.3% of the class, with sole voting and dispositive power over all of these shares.
Baillie Gifford & Co, an investment adviser based in Scotland, states that the AEHR shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company or participating in any control-related transactions.